Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391716 · ClinicalTrials.gov registry record · Phase 2
Gabapentin Treatment of Alcohol Dependence
A Phase 2 study of Alcoholism and Alcohol Dependence, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00391716 is a Phase 2 study of Alcoholism and Alcohol Dependence that has completed, run by The Scripps Research Institute. The registered enrollment target is 150 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00391716, a Phase 2 study of Alcoholism and Alcohol Dependence, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Gabapentin treatment for alcohol dependence
Conditions Studied
Interventions
- DRUG placebo
- DRUG Gabapentin 900mg
- BEHAVIORAL behavioral counseling
- DRUG gabapentin 1800mg
Study Locations (1)
California
- The Scripps Research Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-02 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00391716
The ClinicalTrials.gov registry entry for NCT00391716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (60% lower). The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcoholism appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT00391716 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00391716 about?
NCT00391716 is a clinical study titled "Gabapentin Treatment of Alcohol Dependence". Gabapentin treatment for alcohol dependence
What is the current status of trial NCT00391716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-02. Estimated completion is 2010-02.
What conditions does trial NCT00391716 study?
This clinical trial studies the following conditions: Alcoholism, Alcohol Dependence.
What interventions are being tested in trial NCT00391716?
The interventions under investigation include: placebo (DRUG), Gabapentin 900mg (DRUG), behavioral counseling (BEHAVIORAL), gabapentin 1800mg (DRUG).
Who is sponsoring clinical trial NCT00391716?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00391716 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.